{"entity": "publication", "iuid": "d90378fa18cf4fcba2d83c1fc66515d9", "timestamp": "2026-08-26T22:46:44.818Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/d90378fa18cf4fcba2d83c1fc66515d9.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/d90378fa18cf4fcba2d83c1fc66515d9"}}, "title": "Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden.", "authors": [{"family": "Brusselaers", "given": "Nele", "initials": "N", "orcid": "0000-0003-0137-447X", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/70d0a6a2f4eb4272be4865e7e369c0e9.json"}}, {"family": "Sadr-Azodi", "given": "Omid", "initials": "O"}, {"family": "Engstrand", "given": "Lars", "initials": "L"}], "type": "journal article", "published": "2020-04-00", "journal": {"title": "J. Gastroenterol.", "issn": "1435-5922", "volume": "55", "issue": "4", "pages": "453-461", "issn-l": "0944-1174"}, "abstract": "The long-term safety of proton pump inhibitors (PPIs) is increasingly questioned. The aim of our study was to assess the risk of pancreatic cancer among long-term PPI users in Sweden.\n\nThis population-based nationwide Swedish cohort study including 796,492 adult long-term PPI users has been used to calculate the standardized incidence rate ratios (SIRs) and 95% confidence intervals (CI) for pancreatic cancer, stratifying by indications of use, age, sex, and duration of use. The risk among all 20,210 long-term H2-receptor antagonist users was assessed as comparison.\n\nPancreatic cancer was found in 1733 long-term PPI users, and 25 H2-receptor antagonist users. For PPI users, the risk of pancreatic cancer was increased overall (SIRs = 2.22; 95% CI 2.12-2.32) and in all subgroup analyses, with the highest risk among PPI-users younger than 40 years (SIR = 8.90, 95% CI 4.26-16.37), and among individuals with a history of Helicobacter pylori (SIR = 2.99, 95% CI 2.54-3.49). After the first year after enrolment (during which PPI use may be because of early symptoms of pancreatic cancer), the risk remained increased over time, with SIR = 1.57 (95% CI 1.38-1.76) after 5 years. No associations were found for H2-receptor antagonists (SIR = 1.02, 95% CI 0.66-1.51).\n\nThis large study showed an increased risk of pancreatic cancer in long-term users of PPIs in Sweden, in particular among the youngest users.", "doi": "10.1007/s00535-019-01652-z", "pmid": "31811561", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC7080689"}, {"db": "pii", "key": "10.1007/s00535-019-01652-z"}], "notes": [], "created": "2026-08-21T11:07:00.171Z", "modified": "2026-08-21T11:07:00.227Z"}